Beatrice Simeone

Dr. Beatrice Simeone

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
BSBeatrice Simeone
Beatrice Simeone
EMEnrico Maggio
Enrico Maggio
LSLeonardo Schirone
Leonardo Schirone
ERErica Rocco
Erica Rocco
GSGianmarco Sarto
Gianmarco Sarto
CVCarmine Dario Vizza
Carmine Dario Vizza
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) presents a significant diagnostic challenge due to its complex and often nonspecific clinical manifestations. This review outlines a comprehensive approach to the diagnostic assessment of CTEPH, emphasizing the importance of a high index of suspicion in patients with unexplained dyspnea or persistent symptoms post-acute pulmonary embolism. We discuss the pivotal role of multimodal imaging, including echocardiography, ventilation/perfusion scans, CT pulmonary angiography, and magnetic resonance imaging, in the identification and confirmation of CTEPH. Furthermore, the review highlights the essential function of right heart catheterization in validating the hemodynamic parameters indicative of CTEPH, establishing its definitive diagnosis. Advances in diagnostic technologies and the integration of a multidisciplinary approach are critical for the timely and accurate diagnosis of CTEPH, facilitating early therapeutic intervention and improving patient outcomes. This manuscript aims to equip clinicians with the knowledge and tools necessary for the efficient diagnostic workflow of CTEPH, promoting awareness and understanding of this potentially treatable cause of pulmonary hypertension.

25 July 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
BSBeatrice Simeone
Beatrice Simeone
EMEnrico Maggio
Enrico Maggio
LSLeonardo Schirone
Leonardo Schirone
ERErica Rocco
Erica Rocco
GSGianmarco Sarto
Gianmarco Sarto
CVCarmine Dario Vizza
Carmine Dario Vizza
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure. The cornerstone of CTEPH management lies in a multifaceted therapeutic approach tailored to individual patient profiles, reflecting the disease's heterogeneity. This review delves into the current therapeutic strategies for CTEPH, including surgical pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and targeted pharmacological treatments such as PDE5 inhibitors, endothelin receptor antagonists, sGC stimulators, and prostanoids. Lifelong anticoagulation is also highlighted as a preventive strategy against recurrent thromboembolism. Special emphasis is placed on the interdisciplinary nature of CTEPH care, necessitating collaboration among PEA surgeons, BPA interventionists, PH specialists, and thoracic radiologists to ensure comprehensive treatment planning and execution. The review underscores the importance of selecting an appropriate treatment modality based on the patient's specific disease characteristics and the evolving landscape of CTEPH treatment, aiming to improve patient outcomes through integrated care strategies.

17 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LSLUIGI SPADAFORA
LUIGI SPADAFORA
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
MGMattia Galli
Mattia Galli
CCCarlos Collet
Carlos Collet
MBMatteo Betti
Matteo Betti
Marco BernardiMarco Bernardi
Marco Bernardi
Background/Objectives: Anemia and renal impairment are key predictors of adverse outcomes in acute coronary syndromes (ACSs). The hemoglobin-to-creatinine (Hb/Cr) ratio combines these parameters into a simple index. This study aimed to evaluate its prognostic value at discharge in patients with ST-elevation myocardial infarction (STEMI). Methods: The primary endpoint was one-year all-cause mortality; secondary endpoints included major bleeding and the composite of all-cause mortality or reinfarction. Optimal Hb/Cr cut-off values were identified using Liu’s method. Multivariable logistic regression and propensity score matching were used to assess associations with outcomes. Results: We analyzed 11,236 STEMI patients from the PRAISE registry with available hemoglobin and creatinine values at discharge. The optimal cut-points were 13.68 for mortality and 14.42 for secondary endpoints. Patients were stratified into low (<13.68; 26.5%) and high (≥13.68; 73.5%) Hb/Cr groups. The low Hb/Cr group was older, had more comorbidities, and received less intensive therapy. At one year, low Hb/Cr patients had significantly higher rates of all-cause mortality (8.7% vs. 2.4%), major bleeding (5.0% vs. 2.4%), and the composite outcome (11.5% vs. 4.9%). In the multivariate logistic regression, the Hb/Cr ratio was inversely associated with all outcomes, namely all-cause mortality (odds ratio [OR] 0.94; 95% confidence interval [CI]: 0.92–0.96), major bleeding (OR 0.96; 95% CI: 0.94–0.97), and the composite endpoint (OR 0.93; 95% CI: 0.91–0.96). The Hb/Cr ratio outperformed hemoglobin and creatinine alone in predicting mortality (AUC 0.684 vs. 0.649 and 0.645; p < 0.001). Conclusions: The Hb/Cr ratio is independently associated with one-year adverse outcomes in STEMI and may serve as a simple marker of increased vulnerability. Prospective studies are needed to validate its clinical utility.

4 March 2025 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
ERErica Rocco
Erica Rocco
MCMarco Ciacciarelli
Marco Ciacciarelli
SBSalvino Bilancini
Salvino Bilancini
SFSonia Ferri
Sonia Ferri
APAlessandro Polidoro
Alessandro Polidoro
Luigi IulianoLuigi Iuliano
Luigi Iuliano

7 July 2026 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Open access
BSBeatrice Simeone
Beatrice Simeone
ERErica Rocco
Erica Rocco
LSLuigi Spadafora
Luigi Spadafora
SSSebastiano Sciarretta
Sebastiano Sciarretta
MGMichele Golino
Michele Golino
Anthracyclines remain a cornerstone of cancer therapy but are associated with a spectrum of cardiovascular toxicity, ranging from subclinical myocardial injury to overt heart failure (HF). Despite strong biological rationale, the role of universal pharmacologic prophylaxis remains uncertain. In this context, the recent meta-analysis by Pizzi et al. provides a timely synthesis of randomized evidence evaluating angiotensin-converting enzyme inhibitors (ACEi) for the prevention of anthracycline-related cardiotoxicity. The analysis demonstrates a statistically significant attenuation of left ventricular ejection fraction decline with ACEi prophylaxis, although the absolute effect size is modest and accompanied by substantial heterogeneity. Importantly, the magnitude of benefit appears to be context-dependent, with more consistent effects observed in higher-risk settings, such as combined anthracycline and trastuzumab exposure or in patients with early markers of myocardial injury. Contemporary data suggest that declining event rates and improved supportive care may limit the ability of prophylaxis trials to detect clinically meaningful differences in low-risk populations. Furthermore, the absence of significant effects on clinical endpoints underscores the limitations of current surrogate markers and trial design. Emerging evidence supports a more nuanced, risk-adapted approach, integrating early detection strategies such as global longitudinal strain and biomarker-guided intervention. Within this framework, ACEi prophylaxis may be most appropriately targeted to patients with higher baseline risk or early evidence of myocardial injury, rather than applied universally. Future studies should prioritize risk enrichment, standardized imaging protocols, and clinically meaningful outcomes to better define the role of cardioprotective strategies in cardio-oncology.

18 June 2026 in Current Cardiology Reviews
Verified
Journal Article
Closed access
PDF file
BSBeatrice Simeone
Beatrice Simeone
EDElisa Dietrich
Elisa Dietrich
GSGianmarco Sarto
Gianmarco Sarto
MGMaria Elisabetta Greco
Maria Elisabetta Greco
MFMaurizio Forte
Maurizio Forte
CPConcetta Potenza
Concetta Potenza
Introduction: Dermatological disorders are emerging as important indicators of systemic health and have drastic implications for cardiovascular disease (CVD). Skin and cardiovascular diseases share common pathophysiological mechanisms, including chronic inflammation, oxidative stress, and endothelial dysfunction. These overlapping pathways contribute to the increased cardiovascular (CV) risk observed in patients with inflammatory and genetic dermatological conditions, such as psoriasis, atopic dermatitis, and systemic lupus erythematosus. Methods: This narrative review was conducted by evaluating current evidence from peerreviewed literature on the association between dermatological disorders and cardiovascular risk. Particular attention was given to pathophysiological mechanisms and therapeutic implications relevant to both specialties. Results and Discussion: Since systemic inflammation is a major risk factor for CVD, treatments that reduce the inflammatory burden represent promising strategies to prevent or mitigate cardiovascular complications in patients with dermatological conditions. Traditional therapies (e.g., methotrexate and statins) remain the gold standard to reduce CV risk. In addition, advances in the field of inflammation—such as inhibitors targeting IL-17 and IL-23 pathways—along with new systemic biomarkers and the development of targeted therapies, are paving the way for improved patient stratification and personalized approaches. Conclusions: This review highlights the importance of interdisciplinary collaboration in optimizing patient outcomes and emphasizes the need for closer integration of dermatological and cardiological expertise. Future research should focus on clarifying molecular mechanisms, identifying therapeutic targets, and refining shared clinical guidelines. By bridging dermatology and cardiology, this review underscores the potential for earlier detection, better risk prediction, and integrated management of coexisting dermatological and cardiovascular conditions.